Combination hormonotherapy with tamoxifen and fluoxymesterone in patients with advanced breast cancer relapsing on hormonotherapy

Aron Goldhirsch, Urs Leuenberger, Hans Jörg Ryssel, Franco Cavalli, Roland W. Sonntag, Rudolph A. Joss, Kurt W. Brunner

Research output: Contribution to journalArticlepeer-review

Abstract

33 patients were treated with a combination of tamoxifen and fluoxymesterone (10 mg t.i.d. each) after progression on prior hormonotherapy (HT). 6 of 22 patients (27%) exhibiting a partial response (PR) or stable disease (NC) on previous HT responded to the combination (median time to relapse 7 months, range 3.5 to 17+ months). 11 (50%) maintained NC (median duration 5 months, range 2+ to 9.5 months). No response has been seen in 11 patients who experienced progressive disease during prior hormonal manipulation or who were not evaluable for response to prior HT. The overall response rate was 18% for the patient population as a whole (responders and nonresponders to previous HT), which most probably would be similar to the response rate if these patients received only fluoxymesterone.

Original languageEnglish
Pages (from-to)284-286
Number of pages3
JournalOncology
Volume39
Issue number5
DOIs
Publication statusPublished - 1982

Keywords

  • Advanced breast cancer
  • Combination hormonotherapy
  • Tamoxifen Fluoxymesterone

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Combination hormonotherapy with tamoxifen and fluoxymesterone in patients with advanced breast cancer relapsing on hormonotherapy'. Together they form a unique fingerprint.

Cite this